Welcome to the Digital HER2-Targeted Therapies Summit 2021 - The First Conference Focused on Exploring New Frontiers of HER2 as a Pan-Tumor Target
HER2 expressing patients are experiencing drug resistance, suboptimal duration of response and refractory/relapsed disease, stimulating new frontiers for HER2-targeted drug development. Impressive clinical data are being reported for next-generation anti-HER2 approaches in breast, gastric, lung, colon cancers and beyond. However, efforts to expand the clinical utility of HER2 as a pan-tumor target don’t stop there, with a flood of news on priority reviews, fast track approvals, IPOs and collaborations.
As such, the HER2-Targeted Therapies Digital Summit 2021 arrives as the first ever cross-disciplinary meeting for large pharma, biotech and academia, to maximize HER2-targeting in the pantumor setting. Expect to be involved in interactive discussions on the diversity of next generation anti-HER2 drugs in the clinic including ADCs, bispecifics, TKIs, CAR approaches and more.
This is your chance to overcome challenges of resistance against anti-HER2 approaches and accelerate therapies to patients in need. Examine HER2 heterogeneity across different tumors to maximize the commercial potential of this target. Discuss how quantitative pathology is helping to match HER2 expression with therapeutic response.
As the clinical and commercial growth potential of next generation HER2-targeted therapies becomes apparent, this is a timely and comprehensive forum giving you the opportunity to connect with leaders of the field directly.
Be part of this unique forum to strengthen your pipeline by expanding the clinical utility of your anti-HER2 candidate across tumor settings with the greatest unmet medical need.
Time: 8:00 am - 4:30 pm
Conference Pass: USD 1999.00